• 1
    Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic 2010. Geneva, Switzerland: UNAIDS; 2010.
  • 2
    Mathers B. M., Degenhardt L., Ali H., Wiessing L., Hickman M., Mattick R. P. et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010; 375: 10141028.
  • 3
    Alistar S. S., Owens D. K., Brandeau M. L. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. PLoS Med 2011; 8: e1000423.
  • 4
    Des Jarlais D. C., Feelemyer J. P., Modi S. N., Arasteh K., Mathers B. M., Degenhardt L. et al. Transitions from injection-drug-use-concentrated to self-sustaining heterosexual HIV epidemics: patterns in the international data. PLoS ONE 2012; 7: e31227.
  • 5
    Altice F. L., Kamarulzaman A., Soriano V. V., Schechter M., Friedland G. H. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet 2010; 376: 5979.
  • 6
    Krupitsky E., Nunes E. V., Ling W., Illeperuma A., Gastfriend D. R., Silverman B. L. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011; 377: 15061513.
  • 7
    Degenhardt L., Mathers B., Vickerman P., Rhodes T., Latkin C., Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 2010; 376: 285301.
  • 8
    Bruce R. D., Dvoryak S., Sylla L., Altice F. L. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine—programme description and policy implications. Int J Drug Policy 2007; 18: 326328.
  • 9
    Schaub M., Chtenguelov V., Subata E., Weiler G., Uchtenhagen A. Feasibility of buprenorphine and methadone maintenance programmes among users of home made opioids in Ukraine. Int J Drug Policy 2010; 21: 229233.
  • 10
    Sylla L., Bruce R. D., Kamarulzaman A., Altice F. L. Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. Int J Drug Policy 2007; 18: 306312.
  • 11
    Cohen J. No opiate substitutes for the masses of IDUs. Science 2010; 329: 165167.
  • 12
    Wolfe D., Carrieri M. P., Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 2010; 376: 355366.
  • 13
    Jolley E., Rhodes T., Platt L., Hope V., Latypov A., Donoghoe M. et al. HIV among people who inject drugs in central and eastern Europe and central Asia: a systematic review with implications for policy. BMJ Open 2012; 2: e001465.
  • 14
    Mimiaga M. J., Safren S. A., Dvoryak S., Reisner S. L., Needle R., Woody G. ‘We fear the police, and the police fear us’: structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev, Ukraine. AIDS Care 2010; 22: 13051313.
  • 15
    Ukraine Ministry of Health. Pro zatverdzennia Poriadku provedennia zamisnoji pidtrimuval'noji terapiji xvoryx z opiodnoju zalezhnistju (Approval of the order for carrying out substitution support therapy for patients with opioid dependence). 2012. Available at: (accessed 14 April 2013) (Archived at on 25 May 2013).
  • 16
    Kakko J., Svanborg K. D., Krk M. J., Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003; 361: 662668.
  • 17
    Cohen J. Law enforcement and drug treatment: a culture clash. Science 2010; 329: 169.
  • 18
    Judice N., Zaglada O., Mbuya-Brown R. HIV Policy Assessment: Ukraine. Washington, DC: Futures Group, Health Policy Project; 2011.
  • 19
    Ukrainian State Drug Control Committee. Project National Drug Strategy of Ukraine for the Period through 2020. 2013. Available at: (accessed 23 April 2013) (Archived at on 25 May 2013).